Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Phase one…..

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Mar 25, 2022 9:50pm

83 Views

Post# 34547520

RE:RE:RE:Phase one…..

I am as impatient and frustrated as anyone, but as you say we are still here, the company hasen't folded, and I am waiting hopefully for some good news sooner than later. But I am not putting more into this without a big turnaround. There have been too many moments where hopes have been raised only to be followed by more disappointment.

I have had conversations with Bob where he has explained why the delays are happening, and it makes sense, but I would not post here only to, as you say, be $hit on even more. But I am confident it will entually transpire.

I would welcome a conversation about this but not in this forum, so if you are interested feel free to reach out.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments